Axsome Therapeutics price target raised to $153 from $133 at Needham
Needham raised the firm’s price target on Axsome Therapeutics (AXSM) to $153 from $133 and keeps a Buy rating on the shares. The company’s Q4 ...
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with ...
L.A. public school cell phone ban takes effect Tuesday
Starting Tuesday, students with the Los Angeles Unified School District will no longer be allowed to use their cellphones on ...
As Caterpillar Digs Itself Into A Hole, Option Trade Offers A Way To Profit
Caterpillar stock looks like a potential bearish candidate after breaking below the 200-day moving average Wednesday.